anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Left ventricular global longitudinal strain (LV GLS) on echocardiography is a sensitive yet clinically significant marker of myocardial dysfunction. Reduced LV GLS is prevalent in adults with chronic kidney disease and hypertension and is associated with adverse cardiovascular outcomes. It may be a biomarker of chronic kidney disease-associated myocardial dysfunction in children, but data are limited. Our objective was to describe LV GLS in the CKiD study (Chronic Kidney Disease in Children) and to examine the association between blood pressure (BP) and reduced LV GLS.
METHODS: A single apical 4-chamber view was used to estimate LV GLS. Our main analyses examined the association of clinic BP with the absolute value of LV GLS and LV GLS dichotomized at 16. Sensitivity analyses using 24-hour ambulatory BP monitoring data were also performed. Generalized estimating equations were used to account for within-person correlation and to estimate robust SEs for 95% CIs. Covariates in adjusted models included: age, sex, race, estimated glomerular filtration rate, urine protein, hemoglobin, left ventricular hypertrophy, and the use of renin-angiotensin system inhibitors.
RESULTS: LV GLS was measured in 962 person-visits. A total of 77 assessments had an LV GLS <16. In adjusted models, both clinic systolic BP (odds ratio, 1.02 [95% CI, 1.01-1.03]) and diastolic BP (odds ratio, 1.02 [95% CI, 1.00-1.03]) percentiles were associated with LV GLS <16. Having awake or nighttime diastolic BP hypertension on ambulatory BP monitoring was significantly associated with a lower absolute value of LV GLS.
CONCLUSIONS: Office systolic and diastolic hypertension was associated with diminished LV GLS. Only diastolic hypertension detected on ambulatory BP monitoring was associated with lower LV GLS.
This arm will receive a handout about parenting techniques in Spanish during month 3. They then receive the same parenting curriculum during month 4.
The invention relates to a tooth zirconia/leucite composite porcelain powder and a preparation method thereof. The material includes the following components: 50 to 60 percent of Sio2, 10 to 20 percent of Al2O3, 16 to 30 percent of K2O, 2 to 5 percent of Na2O and 2 to 15 percent of ZrO2. The preparation method of the material relates to: selecting a mineral potassium feldspar powder of the first grade, adding a certain amount of potash, nanometer tetragonal zirconia powder body and ethanol to uniformly mix in a globe mill and acquiring a raw material powder after drying; placing the raw material powder into a corundum crucible to calcine under a temperature of 1000 to 3000 DEG C for 30 to 90 minutes, cooling naturally and acquiring the zirconia/leucite composite porcelain powder with a grain diameter of 10 to 30Mum after crushing the raw material through ball milling. The crystalling phases of the zirconia and the leucite in the porcelain powder are distributed uniformly. The heat expansion coefficient of the powder is (12 to 16) multiplied by 10<-6>K and the anti-bending intensity of the powder is 90 to 130MPa. The invention is also characterized by good color masking property and high fracture toughness property, etc., and lays a foundation for the clinic application of mouth porcelain repairing.
Children aged 5-13 years, all genders, will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Children will be asked to determine if each individual cereal is "child-appealing" (i.e., yes or no). Children will also be asked to rank the cereals in order of their preference (i.e., Most (1) to Least (6)). Children will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did.
AIMS: The optimal sampling methods for detecting human papillomavirus (HPV) in male genital sites remain unclear. This study aimed to assess the performance, acceptability, and comfort of two sampling techniques for male genital HPV detection.
METHODS AND RESULTS: A total of 490 men aged 18-45 were randomly assigned in a 1:1 ratio to undergo either the rub-brush (nail file followed by swab) or brush-only method (swab only) for sampling at external genitalia sites (PGS) and perineum/perianal (PA) sites. HPV distribution, specimen validity (β-globin as a quality reference), and participant acceptability and comfort were evaluated between the two sampling methods. The brush-only method demonstrated non-inferiority in detecting 14 high-risk HPV types (16/18/31/33/35/39/45/51/52/56/58/59/66/68) compared to the rub-brush method in both PGS (18.9% vs. 16.9%) and PA (10.5% vs. 11.9%). Although no significant differences were observed in positive rates for other HPV types, the brush-only method had a significantly higher invalid rate in PA (8.5% vs. 1.5%). Approximately 85.0% of participants reported good acceptability and comfort with both sampling methods, regardless of anatomical sites.
CONCLUSIONS: This study suggests comparable performance, acceptability and comfort between the two sampling techniques for HPV detection. However, the rub-brush method may offer an advantage in higher sample validity.
Recent evidence has pinpointed a key role of the microbiome in human respiratory health and disease. However, significant knowledge gaps still exist regarding the connection between bacterial communities and adverse effects caused by particulate matters (PMs). Here, we characterized the bacterial microbiome along different airway sites in occupational pneumoconiosis (OP) patients. The sequencing data revealed that OP patients exhibited distinct dysbiosis in the composition and function of the respiratory microbiota. To different extents, there was an overall increase in the colonization of microbiota, such as Streptococcus, implying a possible intrusion pathway provided by exogenous PMs. Compared to those of healthy subjects, unhealthy living habits (i.e., smoking) had a greater impact on microbiome changes in OP patients. Importantly, the associations between the bacterial community and disease indicators indicated that specific bacterial species, including Prevotella, Actinobacillus, and Leptotrichia, might be surrogate markers of OP disease progression. Collectively, our results highlighted the potential participation of the bacterial microbiota in the pathogenesis of respiratory diseases and helped in the discovery of microbiome-based diagnostics for PM-induced disorders.
A traditional Chinese medicinal composition for treating diabetes relates to the technical field of Chinese herbal medicines. The traditional Chinese medicinal composition comprises the following bulk drugs: by weight, 35-45 parts of rhizoma atractylodis, 35-45 parts of Rhizoma Alismatis, 25-35 parts of root of kudzu vine, 5-15 parts of dendrobium, 45-55 parts of astragali radix, 15-25 parts of red sage root, 5-15 parts of radix scrophulariae, 10-20 parts of Cornus officinalis, 25-35 parts of Tuber of Dwarf Lilyturf, 15-25 parts of Chinese yam, 25-35 parts of Euonymus Alatus and 15-25 parts of rehmanniae radix. Selection and compatibility of traditional Chinese medicinal materials accord with dialectical theories in Chinese Medicine, and a preparation method of the traditional Chinese medicinal composition is simple. After compatibility, a water decoction is prepared. The traditional Chinese medicinal composition has a remarkable effect of treating diabetic patients and has no toxic or side effect. Complementary purpose in traditional Chinese medicine compatibility is achieved.
The SAFMA cohort was an ad hoc study formed into the recruitment of the acute care for elders in the geriatric department of Martinique university Hospitals. The inclusion of subjects ran from January 1st 2012 to June 30th 2012. To be eligible, patients had to be 75 or over and hospitalised for acute condition. Each patient was visited by a specialist in geriatrics familiar with the survey procedures. In the course of this interview, patients were informed about the study, prior to signing the consent form. If the clinical status and/or the cognitive status of the patient did not enable informed consent, the interviewer referred to the subject's representative. Follow-up was performed by visits and telephone interview till 36 months.
Topiramate, USP, is a sulfamate-substituted monosaccharide. QUDEXY XR (topiramate) extended-release capsules are available as 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg capsules for oral administration as whole capsules or opened and sprinkled onto a spoonful of soft food.

Topiramate is a white to off-white powder. Topiramate is freely soluble in polar organic solvents such as acetonitrile and acetone; and very slightly soluble to practically insoluble in non-polar organic solvents such as hexanes. Topiramate has the molecular formula C 12H 21NO 8S and a molecular weight of 339.4. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula: 

QUDEXY XR (topiramate) extended-release capsules contain beads of topiramate in a capsule. The inactive ingredients are microcrystalline cellulose, hypromellose 2910, ethylcellulose, diethyl phthalate.

In addition, the capsule shells for all strengths contain hypromellose 2910, titanium dioxide, black iron oxide, red iron oxide and/or yellow iron oxide, black pharmaceutical ink, and white pharmaceutical ink (200 mg only).
OBJECTIVE: To investigate the association between sarcopenia, as appraised with CT-derived muscle metrics, and cardiovascular status, as assessed via coronary CT angiography (CCTA) using the Coronary Artery Disease-Reporting and Data System (CAD-RADS) and with pericoronary adipose tissue (pCAT) metrics.
METHODS: A retrospective observational study conducted on patients who underwent CCTA. The cross-sectional area (CSA) and attenuation values of the paravertebral muscles at the T8 level and the pectoralis major muscles at the T6 level were measured. The patient height was employed for the normalization of the skeletal muscle CSA. The pCAT attenuation around the coronary arteries was assessed, and the CAD severity was graded using the CAD-RADS reporting system. Regression analyses were performed to assess the impact of demographics, clinical factors, and CT variables on the CAD-RADS and pCAT.
RESULTS: A total of 220 patients were included (132 males, median age 65 years). Regression analyses showed the associations of CAD with age and sex (p < 0.001). Familiarity with CAD was related to the left anterior descending artery pCAT (p = 0.002) and circumflex artery pCAT (p = 0.018), whereas age was related to the left anterior descending artery pCAT (p = 0.032). Weak positive correlations were found between the lower muscle density and lower pCAT attenuation (ρ = 0.144-0.240, p < 0.039).
CONCLUSIONS: This study demonstrated weak associations between the sarcopenia indicators and the cardiovascular risk, as assessed by the CAD severity and pCAT inflammation. However, these correlations were not strong predictors of CAD severity, as age and traditional cardiovascular risk factors overshadowed the impact of sarcopenia in the cardiovascular risk assessment.
This is a randomized, open-label, single center, exploratory, Phase 1 study to explore changes and resistance patterns of bacteria in the oral flora of healthy male and female adult subjects. The study is to enroll approximately 140 healthy subjects. Approximately 70 subjects are to receive levofloxacin once daily for 5 days and 70 are to receive azithromycin once daily for 5 days. Male or female healthy subjects, 18 years or older may participate. Subjects will be treated on an outpatient basis at a Phase 1 facility. Laboratory testing (blood and urine collection) and microbiologic testing (throat swab) will be performed before dosing with study drug at the Study Entry (Visit 1). Subjects will return daily to the testing facility for their once-daily dosing of study drug for Visits 2 through 5 for a total of 5 consecutive days. At Visit 5 laboratory and microbiologic testing will be performed. Subjects will again return to the testing facility for the 2-Week (Visit 6), 4-Week (Visit 7) and 6-Week (Visit 8) Post-Therapy Visits to undergo microbiologic testing (throat swab). The primary endpoint is the emergence of bacterial resistance in the oropharyngeal flora starting prior to the initiation of study drug through a 6-week observation period. Microbiologic testing (throat swab) will be conducted prior to dosing on Day 1 and following dosing on Days 5, 19, 33, and 47. Safety assessments will be conducted prior to drug administration, during study drug treatment, and at the end-of-therapy visit. These included clinical laboratory evaluations, vital signs, physical examinations, pregnancy testing, and collection of adverse events. Serious adverse events will be collected for 30 days following the last dose of study drug. Levofloxacin Once-Daily 750 mg PO For 5 Days And Azithromycin Once-Daily 500 mg PO On Day One And Then 250 mg On Days 2 Through 5
PURPOSE: A pharmacological composition containing statin compound and CoQ10 compound is provided to promote complex physiologically active function. CONSTITUTION: A liquid culture containing drug-effective physiologically active material is prepared by inoculating Monascus spp. to a liquid medium containing drug-effective natural powder and culturing. The liquid medium is obtained by adding drug-effective natural materials to rice flour, flucose, peptone, glyacine, and broth. The drug-effective natural powder ingredient has ginseng powder, red pimento powder, mushroom powder, or tomato powder. The Monascus spp. is M. anka, M. purpureus, M. pilosus, M. rubber, M. araneosus, or M. kaoliang ATCC 595.
This would be a prospective study for which patients not prescribed chronic pain medication (defined as not using narcotic medications in 3 months prior to surgery) and presenting for surgery would be recruited. Preop administration of sedating medications (i.e. midazolam) would be avoided. On the day of surgery, once in OR and standard ASA monitors placed, a standardized dose of 2mcg/kg ideal body weight IV fentanyl is administered. The patient is then monitored for respiratory depression for 5 minutes prior to administration of additional induction agents. \[would include respiratory rate, with RR \< 10, or O2 Sat \< 90%\]. Would not provide supplemental oxygen during this time unless patient was already on supplemental oxygen. Patient would then be preoxygenated and general anesthesia induced. Once general anesthesia is induced, a blood sample is collected and stored. \[sample could also be collected in preop upon IV placement\]. Blood will be tested for Single Nucleotide Polymorphisms of genes related to opioid-induced analgesia. \[Potential target genes listed in 7.0-1\] This genomic data will be evaluated for any correlations of the presence of opioid-related SNPs and concomitant opioid-induced respiratory depression.
PURPOSE:To attain a back-up copy system without using the same volume name by performing a back-up copy operation to a copy receiver memory medium from a copy sender memory medium with use of the different volume names and changing the different volume names into the original ones to the copy sender memory medium after the end of the back-up copy operation. CONSTITUTION:The volume name BB of a copy sender memory medium 52 is changed into another volume name XX prior to a back-up copy operation. Then the unchanged name BB of the medium 52 is added to a copy receiver memory medium 5N. The medium 5N is set out of the control of a picture data base device after the back-up operation, and the name XX of the medium 52 is turned again into the original name BB. Therefore two memory media of the same volume name are never present in a back-up copy state owing to a fact that both media 52 and 5N have the different volume names from each other. Thus the back-up copy operation can be executed as it is without changing the constitution of a back-up copy.
Since IOPIDINE* 1% Ophthalmic Solution is a potent depressor of IOP, patients who develop exaggerated reductions in IOP should be closely monitored. Although the acute administration of two drops of IOPIDINE 1% Ophthalmic Solution has minimal effect on heart rate or blood pressure in clinical studies evaluating patients undergoing anterior segment laser surgery, the preclinical pharmacologic profile of this drug suggests that caution should be observed in treating patients with severe cardiovascular disease including hypertension. IOPIDINE 1% Ophthalmic Solution should also be used with caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, chronic renal failure, Raynaud’s disease or thromboangiitis obliterans.

The possibility of a vasovagal attack occurring during laser surgery should be considered and caution used in patients with history of such episodes.

Topical ocular administration of two drops of 0.5%, 1%, and 1.5% IOPIDINE Ophthalmic Solution to New Zealand Albino rabbits three times daily for one month resulted in sporadic and transient instances of minimal corneal cloudiness in the 1.5% group only. No histopathological changes were noted in those eyes. No adverse ocular effects were observed in cynomolgus monkeys treated with two drops of 1.5% IOPIDINE Ophthalmic Solution applied three times daily for three months. No corneal changes were observed in 320 humans given at least one dose of IOPIDINE 1% Ophthalmic Solution.
The present invention discloses a traditional Chinese medicine composition for treating chronic sinusitis by internal administration, which pertains to the field of traditional Chinese medicine. The traditional Chinese medicine composition for treating chronic sinusitis by internal administration is characterized in that the parts by weight of the pharmaceutical raw materials to make the active ingredients are as follows: 10g of biond magnolia flower, 10g of dwarf lilyturf tuber, 6g of common anemarrhena rhizome, 6g of baical skullcap root, 4g of cape jasmine fruit, 8g of lancelesf lily bulb, 8g of loquat leaf, 5g of largetrifoliolious bugbane rhizome, 5g of liquoric root, 3g of manchurian wildginger and 1g of borneol. The present invention is taken by one dose each day and two times of oral administration in the morning and evening. 10 days is a treatment course. The present invention has the effects of dispelling wind, clearing heat, expelling pus and anti-inflammatory. The present invention achieves the unexpected remarkable effects when in the treatment course of the chronic sinusitis.
Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
PROBLEM TO BE SOLVED: To prepare a hair cosmetic giving excellent gloss, moist feeling and smooth touch to hair and having proper hairdressing property by mixing an amphoteric polymer and a polyoxyalkylene alcohol ether with a specific compound. SOLUTION: This cosmetic is prepared by mixing 0.05-15wt.% of an amphoteric polymer and 0.05-15wt.% of a polyoxyalkylene alcohol ether with 0.1-20wt.% of an organic acid and/or its salt. The amphoteric polymer preferably contains a unit of formula I (R1 is H or methyl; R2 , R5 are each a hydrocarbon; R3 , R4 are each H or a hydrocarbon; A is O or NH etc.). An especially preferable compound is expressed in formula II (R6 is R1 ; R7 is a hydrocarbon; n and m are integers). A compound of formula III (R8 is a hydrocarbon; p is an integer) is preferred as the polyoxyalkylene alcohol ether. The organic acids, for example, are citric acid, lactic acid, pyrrolidonecarboxylic acid, etc., and their salts are Na salt, Li salt, Mg salt, K salt and Ca salt. This hair cosmetic is free from oil stain of hair and has a good stretchability on hair and affinity to hair.
PURPOSE:To disperse uniformly an aq. insoluble substance into an aq. system and to solubilize it by solubilizing the aq. insuluble substance in the aq. system added with a surface-active agent contg. the specified quantity of glycerin and 14-24C unsaturated fatty acid. CONSTITUTION:The following surface-active agent is blened into an aq. system wherein the concn. contained with monoester of both triglycerin and 14-24C unsaturated fatty acid or alpha-branched fatty acid is >=90wt% per total wt%. An aq. insoluble substance is added into the aq. system blended with the surface- active agnet, uniformly dispersed and plasticized. The blended quantity of the surface-active agent into the aq. system is normally 0.5-20wt% preferably 0.5-10wt%. As the aq. insoluble substance plasticized by this method, there are animal and vegetable fat and oil, ester interchanged fat and oil, fatty acid ester, fatty alcohol, fatty hydrocarbon, aromatic hydrocarbon and various min eral oils.
Questions: Does exercise improve physical performance, activity, and quality of life in obese diabetic patients with chronic kidney disease? Design: Randomized controlled trial with concealed allocation, intention-to-treat analysis, and blinded assessment.

Participants: Sixty people aged between 35and 60 years were admitted to a department of Internal medicine .Cairo University hospitals divided randomly into two Groups Intervention: group 1 received aerobic exercises. Patients exercise at 40 to 60% of maximum heart rate. The exercise period comprised the following: the warming up phase (3-5 min), which included aerobic movement exercise of range of motion joints: rotating the wrist (20 rpm clockwise and 20 rpm counter clockwise), wrist up and down (up to 20 moves on the forearm), ankle twisting motion (40 rotations clockwise and counterclockwise around the ankles), and ankles up and down (20 times); the actual phase (20-30 min), which included cycle ergo meter exercise with 12-13 rated perceived exertion; and finally the cooling down phase (3-5 min) in the form of the same aerobic movements as performed in the warming up phase. Exercises done three times per week for three months and group 2 received resistance exercises.training of the lower extremities was performed three times per week for three months. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum repetition maximum(RM) using ankle weights that can be adjusted in 1 lb. increments. A RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3 RM for two sets of 10 repetitions and was increased to three sets as tolerated. When patients could perform three sets with correct technique, the weight was increased. In addition to knee extension and hip flexion and abduction, ankle dorsiflexion and plantar flexion were performed during each exercise session Outcome measures: physical activity was measured via timed up and go test, sit to stand test, number of sit-to-stand-to-sit cycles in 60 seconds, 6 minutes walking test. Obesity was measured by BMI, waist circumference and waist to hip ratio. Also Blood pressure (systolic/diastolic blood pressures, Mean blood pressure, heart rate and blood glucose were measured before exercise. The perception of exercise intensity was assessed by Original Borg Scale. All measurements were taken at the beginning and after three months of treatment.